Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

(Impact Journals LLC) All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients
Source: EurekAlert! - Biology - Category: Biology Source Type: news